glp 1 receptor agonist use and risk of suicide death GLP-1 therapy may reduce suicidal ideation for adolescents with obesity Exploring the connection between semaglutide

Ozempic can be difficult to get and isn't appropriate for everyone

The World Obesity Atlas 2024 reports over 1.5 billion projected cases by 2035, highlighting its growing threat among pediatric and adult populations globally

The messaging is about affordability and access

Preclinical and initial human studies suggest that glucagon-like peptide-1 receptor agonists may be promising treatments for alcohol use disorder, but existing approved treatments should be used until safety and efficacy is demonstrated in clinical trials.

Are YOU safe?

Starting Wednesday, Medicare will help pay for some GLP-1 medications for weight loss